Methods and devices for renal nerve blocking

Patent metadata

Field	Value
Publication number	US-10376516-B2
Application number	US-201815960596-A
Country	US
Kind code	B2
Filing date	Apr 24, 2018
Priority date	Apr 8, 2002
Publication date	Aug 13, 2019
Grant date	Aug 13, 2019

Abstract

Methods for treating a hypertensive human patient are disclosed herein. A method in accordance with one embodiment comprises delivering a neuromodulatory agent to a renal nerve of the patient via an intravascularly positioned drug delivery catheter. The method includes at least partially blocking neural activity along the renal nerve with the neuromodulatory agent, which results in a therapeutically beneficial reduction in blood pressure of the patient.

First claim

What is claimed is:

1. A method, comprising:
delivering a neuromodulatory agent to a renal nerve of a hypertensive human patient via a drug delivery catheter; and
at least partially blocking neural activity along the renal nerve to and from a kidney of the patient with the neuromodulatory agent,
wherein at least partially blocking neural activity along the renal nerve results in a therapeutically beneficial reduction in blood pressure of the patient.

2. The method of claim 1 , further comprising removing the drug delivery catheter from the patient after delivering the neuromodulatory agent to conclude the procedure.

3. The method of claim 1 , further comprising positioning the drug delivery catheter under guidance imaging before delivering the neuromodulatory agent.

4. The method of claim 3 wherein positioning the drug delivery catheter under guidance imaging comprises positioning the drug delivery catheter under fluoroscopic guidance.

5. The method of claim 1 , further comprising determining whether neural activity along the renal nerve has been substantially blocked.

6. The method of claim 5 wherein determining whether neural activity has been substantially blocked comprises electrically stimulating the renal nerve and detecting a response in the patient.

7. The method of claim 1 , further comprising monitoring a parameter of the drug delivery catheter and/or tissue within the patient before and during delivery of the neuromodulatory agent.

8. The method of claim 7 , further comprising altering delivery of the neuromodulatory agent in response to the monitored parameter.

9. The method of claim 1 wherein at least partially blocking neural activity along the renal nerve comprises at least substantially blocking sympathetic neural activity along the renal nerve of the patient.

10. The method of claim 1 wherein delivering a neuromodulatory agent to a renal nerve of a hypertensive human patient comprises delivering a neurotoxin to the renal nerve of the patient.

11. The method of claim 1 wherein delivering a neuromodulatory agent to a renal nerve of a hypertensive human patient comprises delivering alcohol to the renal nerve of the patient.

12. The method of claim 1 wherein delivering a neuromodulatory agent to a renal nerve of a hypertensive human patient comprises delivering phenol, ketamine, and/or an antidepressant to the renal nerve of the patient.

13. The method of claim 1 wherein at least partially blocking neural activity along the renal nerve with the neuromodulatory agent comprises denervating a kidney of the patient.

14. The method of claim 1 wherein at least partially blocking neural activity along the renal nerve with the neuromodulatory agent comprises ablating the renal nerve via the neuromodulatory agent.

15. The method of claim 1 wherein at least partially blocking neural activity along the renal nerve with the neuromodulatory agent further results in a reduction of systemic sympathetic tone in the patient.

16. The method of claim 1 , further comprising positioning at least a portion of the drug delivery catheter within a periarterial space of the patient before delivering the neuromodulatory agent.

17. The method of claim 16 wherein positioning at least a portion of the drug delivery catheter within the periarterial space comprises positioning a distal tip of the drug delivery catheter within renal fascia of the patient.

18. The method of claim 16 wherein positioning at least a portion of the drug delivery catheter within the periarterial space comprises positioning a distal tip of the drug delivery catheter within a target site in continuity with a periarterial fat tissue layer surrounding a renal pedicle of the patient.

19. The method of claim 1 wherein delivering a neuromodulatory agent to a renal nerve of a hypertensive human patient comprises positioning a needle within a periarterial space of the patient and injecting the neuromodulatory agent via the needle into the periarterial space of the patient.

20. The method of claim 19 wherein positioning a needle within a periarterial space of the patient comprises positioning the needle under CT guidance.

Assignees

• Medtronic Ardian Luxembourg

Inventors

• Gelfand Mark
• Levin Howard R

Classifications

• A61N1/326

  for promoting growth of cells, e.g. bone cells · CPC title

• A61K9/0004

  Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61M2005/14513

  with secondary fluid driving or regulating the infusion · CPC title

• A61M5/1723

  using feedback of body parameters, e.g. blood-sugar, pressure (measurement of body parameters A61B5/00) · CPC title